NABAS AS
Keywords
productionmedicinal substancesdrugsantibioticsbasic vitaminssalicylic acido-acetylsalicylic acidprocessing of blood
Organization
- CEO
- PL
Per Lundell1986
- Chairman of the board
- PL
Per Lundell1986
- Years since formation
- 27 years
- since Jan 2, 1997
- Type
- Limited company
- VAT registered
- Yes
- Number of employees
- 10
Ownership
- Number of shares and share classes
- 111,000
- 1 share class
- Total number of shareholders
- 3
- 1 company, 2 persons
- Belongs to group of
Financials
- Total operating income 2023
- 10,726,880
- NOK
- Annual total result 2023
- 103,819
- NOK
- Total equity 2023
- 13,703,613
- NOK
Last update: Oct 14, 2024
Management
Management / administration
| Name | Role | Shares |
|---|---|---|
PL 1986 | Managing Director/CEO | 65.02 % indirectly |
Board
| Name | Role | Shares |
|---|---|---|
PL 1986 | Chairman | 65.02 % indirectly |
AT | Board Member | 4.95 % directly |
| Board Member | - |
Others
| Name | Role | Shares |
|---|---|---|
| Auditor | - | |
| Accountant | - | |
| Accountant | - |
Top 10 individual shareholders
| Name | Role | Shares |
|---|---|---|
PL 1986 | Managing Director/CEO, Chairman | 65.02 % indirectly |
ML | - | 30.03 % directly |
AT | Board Member | 4.95 % directly |
Last update: Aug 7, 2024
Ownership
Company shareholders
| Name | Share class | Number of shares | Share |
|---|---|---|---|
| Ordinary shares | 72,167 | 65.02 % | |
ML | Ordinary shares | 33,333 | 30.03 % |
AT | Ordinary shares | 5,500 | 4.95 % |
Shares owned by the NABAS AS
| Name | Share class | Number of shares | Share |
|---|---|---|---|
| Ordinary shares | 30,000 | 100 % | |
| Ordinary shares | 30,000 | 50 % |
Last update: May 24, 2024
Group structure
- Total operating income 2023: NOK 61,000Operating profit 2023: NOK 49,055Employees: 0
Financials
in NOK
Summary
| Year | 2023 | 2022 | 2021 |
|---|---|---|---|
Total operating income | 10,726,880 | 19,914,625 | 9,594,534 |
Annual Total Result | 103,819 | 7,015,823 | 752,688 |
Total assets | 17,326,804 | 16,819,171 | 10,150,685 |
Total liabilities | 3,623,191 | 3,172,377 | 3,858,658 |
Total equity | 13,703,613 | 13,646,794 | 6,292,027 |
P&L
| Year | 2023 | 2022 | 2021 |
|---|---|---|---|
Total operating income | 10,726,880 | 19,914,625 | 9,594,534 |
Total operating costs | 11,108,844 | 13,123,639 | 8,841,884 |
Operating result | -381,964 | 6,790,986 | 752,650 |
Financial income/costs | 485,783 | 224,837 | 37 |
Profit before tax | 103,819 | 7,015,823 | 752,688 |
Total tax & extraordinary income/cost | 0 | 0 | 0 |
Annual Total Result | 103,819 | 7,015,823 | 752,688 |
Balance overview
| Year | 2023 | 2022 | 2021 |
|---|---|---|---|
Total fixed assets | 237,441 | 547,214 | 507,975 |
Total current assets | 17,089,363 | 16,271,957 | 9,642,710 |
Total assets | 17,326,804 | 16,819,171 | 10,150,685 |
Short term debt | 3,623,191 | 3,172,377 | 3,858,658 |
Long term debt | 0 | 0 | 0 |
Total liabilities | 3,623,191 | 3,172,377 | 3,858,658 |
Contributed capital | 210,000 | 210,000 | 210,000 |
Retained earnings | 13,493,613 | 13,436,794 | 6,082,027 |
Total equity | 13,703,613 | 13,646,794 | 6,292,027 |
Total equity and liabilities | 17,326,804 | 16,819,171 | 10,150,685 |
Classification
Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
C
Main industrial area
Manufacturing
21
Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparations
21.1
Main industrial group
Manufacture of basic pharmaceutical products
21.10
Industrial group
Manufacture of basic pharmaceutical products
21.100
Industrial group
Manufacture of basic pharmaceutical products